# A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)

> **NCT05506943** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Compass Therapeutics** · enrollment: 168 (actual)

## Conditions studied

- Biliary Tract Cancer
- Cholangiocarcinoma
- Gall Bladder Cancer
- Ampullary Cancer

## Interventions

- **DRUG:** CTX-009
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT05506943
- **Lead sponsor:** Compass Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-09
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05506943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05506943, "A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05506943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*